GW Plastics (Bethel, VT), a global contract manufacturer and precision injection molding firm to the healthcare market, announced at the MD&M West exposition (Booth #1909) the completion of a major expansion of their state-of-the-art Dongguan, China, facility in response to their rapidly growing medical device contract manufacturing business.
   
The GW Plastics Dongguan expansion has more than doubled the size of the company’s plant. The new 125,000-square-foot facility will permit the company to streamline its tooling, molding and medical assembly operations, while leaving significant room for future contract manufacturing growth. Now fully operational, the new facility feature product development and in-house tool building services, scientific injection molding capabilities to ensure device standardization, and both automated and manual assembly services.

The company said it plans to enhance their Asia manufacturing capabilities with Liquid Silicone Rubber (LSR) injection molding, as well as customer product development support with increased prototyping, bridge tooling, mold sampling, and short-run production.
   
At the same time, GW Plastics has also broken ground on an expansion of their Royalton, VT, facility. This 21,000-square-foot expansion—scalable to 50,000 square feet—will accommodate additional growth of its thermoplastic and LSR injection molding and medical device contract assembly business.

Expected to be complete later this spring, the expansion will allow for an additional 30 injection molding machines, an enlarged Class 8 LSR cleanroom, and an expansion of its Scientific Molding Process Development and Training Center. This expansion will allow GW Plastics’ affiliate, GW Silicones, to add needed capacity to support ongoing growth. GW Silicones now offers internal LSR tool building capabilities, flash-less molding, automated assembly, and optical grade LSR molding.
   
With the expansion of its facilities in the U.S. and China, GW Plastics provides its customers with the option to commercialize a project domestically in the U.S. or in a low-cost country, delivering a flexible yet cost-effective manufacturing alternative that many companies cannot offer.

“This has allowed us to become a natural extension of our customers’ production capabilities by providing them with a reliable and proven partner to confidently develop and manufacture their finished medical devices across the globe,” said Brenan Riehl, GW Plastics President and CEO.